000164264 001__ 164264
000164264 005__ 20240229123208.0
000164264 0247_ $$2doi$$a10.1002/ctm2.203
000164264 0247_ $$2pmid$$apmid:33135354
000164264 037__ $$aDKFZ-2020-02350
000164264 041__ $$aeng
000164264 082__ $$a610
000164264 1001_ $$0P:(DE-He78)448ff49e51672d79b4747339ac15c898$$aHuang, Lei$$b0$$eFirst author
000164264 245__ $$aDecreasing resection rates for nonmetastatic gastric cancer in Europe and the United States.
000164264 260__ $$aHeidelberg [u.a.]$$bSpringer Open$$c2020
000164264 3367_ $$2DRIVER$$aarticle
000164264 3367_ $$2DataCite$$aOutput Types/Journal article
000164264 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1604486406_26080
000164264 3367_ $$2BibTeX$$aARTICLE
000164264 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164264 3367_ $$00$$2EndNote$$aJournal Article
000164264 500__ $$a#EA:C070#LA:C070#
000164264 520__ $$aResection is the cornerstone of curative treatment for many nonmetastatic gastric cancers (GCs), but the population treatment patterns remains largely unknown. This large international population-based study aimed at investigating the treatment patterns and trends for nonmetastatic GC in Europe and the United States and at exploring factors associated with resection.Data of patients with microscopically confirmed primary invasive GC without distant metastasis from the national cancer registries of the Netherlands, Belgium, Sweden, Norway, Slovenia, and Estonia and the US Surveillance, Epidemiology, and End Results (SEER)-18 Program were retrieved. Age-standardized treatment rates were computed and trends were evaluated using linear regression. Associations of resection with patient and tumor characteristics were analyzed using multivariable-adjusted log-binomial regression. Analysis was performed in each country respectively without pooling.Together 65 707 nonmetastatic GC patients diagnosed in 2003-2016 were analyzed. Age-standardized resection rates significantly decreased over years in all countries (by 4-24%). In 2013-2014, rates varied greatly from 54 to 75%. Patients with increasing ages, cardia cancers, or cancers invading adjacent structure were significantly less frequently resected. Resection was further associated with sex, performance status, comorbidities, tumor histology, tumor size, hospital type, and hospital volume. Association patterns and strengths varied across countries. After multivariable adjustment, resection rates remained decreasing (prevalence ratio = 0.97-0.995 per year), with decreasing trends consistently seen in various subgroups.Nonmetastatic GCs were less frequently resected in Europe and the United States in the early 21st century. Resection rates varied greatly across countries and appeared not to be optimal. Various factors associated with resection were revealed. Our findings can help to identify differences and possibly modifiable places in clinical practice and provide important novel references for designing effective population-based GC management strategies. In Europe and the United States, nonmetastatic gastric cancers were less frequently resected in the early 21st century. Resection rates varied greatly across countries and appeared not optimal. Various factors associated with resection were revealed. Our findings identify differences and possibly modifiable places in clinical practice and provide important novel references for designing effective population-based management strategies.
000164264 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000164264 588__ $$aDataset connected to CrossRef, PubMed,
000164264 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000164264 7001_ $$0P:(DE-HGF)0$$aBalavarca, Yesilda$$b2
000164264 7001_ $$aVerhoeven, Rob H A$$b3
000164264 7001_ $$aRuurda, Jelle P$$b4
000164264 7001_ $$aVan Eycken, Liesbet$$b5
000164264 7001_ $$aDe Schutter, Harlinde$$b6
000164264 7001_ $$aJohansson, Jan$$b7
000164264 7001_ $$aLindblad, Mats$$b8
000164264 7001_ $$aJohannesen, Tom B$$b9
000164264 7001_ $$aZadnik, Vesna$$b10
000164264 7001_ $$aŽagar, Tina$$b11
000164264 7001_ $$aMägi, Margit$$b12
000164264 7001_ $$aBastiaannet, Esther$$b13
000164264 7001_ $$aLagarde, Sjoerd M$$b14
000164264 7001_ $$avan de Velde, Cornelis J H$$b15
000164264 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b16$$udkfz
000164264 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b17$$eLast author$$udkfz
000164264 773__ $$0PERI:(DE-600)2697013-2$$a10.1002/ctm2.203$$gVol. 10, no. 6$$n6$$pe203$$tClinical and translational medicine$$v10$$x2001-1326$$y2020
000164264 909CO $$ooai:inrepo02.dkfz.de:164264$$pVDB
000164264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000164264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000164264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000164264 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000164264 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000164264 9141_ $$y2020
000164264 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-01-14
000164264 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-14
000164264 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-14
000164264 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000164264 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000164264 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000164264 980__ $$ajournal
000164264 980__ $$aVDB
000164264 980__ $$aI:(DE-He78)C070-20160331
000164264 980__ $$aI:(DE-He78)C120-20160331
000164264 980__ $$aI:(DE-He78)HD01-20160331
000164264 980__ $$aUNRESTRICTED